The Notice of Allowance for a new patent on etripamil nasal spray is a positive development for Milestone Pharmaceuticals, as it strengthens their intellectual property portfolio and enhances the commercial potential of their lead product. This could lead to increased investor confidence and a potential rise in stock price.